Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Aflibercept (Eylea) on Type 3 Choroidal Neovascularization
2014-001640-38Phase 4Active
- Sponsor
- CHU de Poitiers
- Start
- Jun 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of aflibercept in Subretinal neovascularization, sponsored by CHU de Poitiers. Primary endpoint: Mean change in BCVA at 52 weeks. Started Jun 2015; status: active.
02
Drugs
aflibercept
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on 2014-001640-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001640-38.